依達(dá)拉奉與奧拉西坦聯(lián)合治療急性腦梗死的臨床研究

程海冰

[摘要] 目的 探討依達(dá)拉奉聯(lián)合奧拉西坦對(duì)急性腦梗死患者的療效及對(duì)血清炎性因子與氧化應(yīng)激指標(biāo)的影響。方法 選取我院2015年1月～2017年1月收治的急性腦梗死患者104例為研究對(duì)象，均經(jīng)臨床檢查確診，根據(jù)不同治療方法分為兩組，兩組患者均給予抗感染、腦細(xì)胞保護(hù)、顱內(nèi)壓降低、血壓控制等常規(guī)治療，對(duì)照組（n=52）給予奧拉西坦治療，觀察組（n=52）在對(duì)照組基礎(chǔ)上給予依達(dá)拉奉治療，對(duì)比兩組患者臨床療效、治療前后炎癥因子水平以及氧化應(yīng)激指標(biāo)水平。 結(jié)果 兩組患者總有效率（90.38% vs 73.08%）比較，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療前兩組患者TNF-α、IL-6水平比較差異無統(tǒng)計(jì)學(xué)意義（P>0.05）;治療后觀察組患者TNF-α、IL-6水平明顯低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療前兩組患者M(jìn)DA、SOD水平比較差異無統(tǒng)計(jì)學(xué)意義（P>0.05）;治療后觀察組患者M(jìn)DA水平明顯低于對(duì)照組，SOD水平明顯高于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。 結(jié)論 依達(dá)拉奉聯(lián)合奧拉西坦兩種藥物可以進(jìn)一步降低腦損傷，促進(jìn)神經(jīng)功能恢復(fù)，因此值得臨床推廣。

[關(guān)鍵詞] 依達(dá)拉奉;奧拉西坦;急性腦梗死;臨床療效;血清炎性因子;氧化應(yīng)激指標(biāo)

[中圖分類號(hào)] R743.3? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701（2019）05-0045-03

[Abstract] Objective To investigate the effect of edaravone combined with oxiracetam on patients with acute cerebral infarction and the effect on serum inflammatory factors and oxidative stress indicators. Methods A total of 104 patients with acute cerebral infarction admitted in our hospital from January 2015 to January 2017 were enrolled in the study. All patients were diagnosed by clinical examination. They were divided into two groups according to different treatment methods. Both groups were given conventional treatments such as anti-infective and brain， cytoprotection， intracranial pressure reduction， and blood pressure control. The control group（n=52） was given oxiracetam. The observation group （n=52） was given edaravone on the basis of the treatment of the control group. The patient's clinical efficacy and inflammatory factor levels before and after treatment as well as oxidative stress indicators were compared. Results There was significant difference in the clinical efficacy of two groups （90.38% vs 73.08%）， which was statistically significant （P<0.05）. There was no significant difference in the levels of tumor necrosis-α and interleukin-6 between the two groups before treatment（P>0.05）. The levels of tumor necrosis-α and interleukin-6 in the observation group were significantly lower than those in the control group after treatment， and the difference was statistically significant （P<0.05）. There was no significant difference in the levels of malondialdehyde and superoxide dismutase between the two groups before treatment（P>0.05）. After treatment， the level of malondialdehyde in the observation group was significantly lower than that in the control group， and the level of superoxide dismutase in the observation group was significantly higher than that of the control group， and the difference was statistically significant （P<0.05）. Conclusion Edaravone combined with oxiracetam can further reduce brain damage and promote the recovery of nerve function， so it is worthy of clinical promotion.